DSwiss, Inc. (DQWS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DSwiss, Inc. (DQWS) with AI Score 54/100 (Hold). DSwiss, Inc. is a Malaysian biotech-nutraceutical company that develops and distributes health and beauty products across Asia. Market cap: 0, Sector: Consumer defensive.
Last analyzed: Mar 17, 2026DSwiss, Inc. (DQWS) Consumer Business Overview
DSwiss, Inc. is a biotech-nutraceutical company based in Malaysia, focusing on health and beauty products across Asian markets. With a diverse product line from coffee to skincare, DSwiss aims to address consumer needs in digestive health, immunity, and overall well-being, operating in a competitive consumer defensive sector.
Investment Thesis
DSwiss, Inc. presents a speculative investment opportunity within the biotech-nutraceutical sector, characterized by a small market capitalization of $0.01 billion and negative profitability metrics, including a P/E ratio of -152.18 and a profit margin of -1.2%. The company's diverse product range and geographic reach across Asian markets offer potential growth avenues. However, the company's OTC listing and negative beta of -0.72 indicate higher risk and volatility. Key growth catalysts include expanding its product line and penetrating deeper into existing markets. The company's ability to achieve profitability and manage its operational costs will be crucial in determining its long-term success. Investors should carefully consider the risks associated with investing in a small-cap, OTC-listed company with negative profitability.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -152.18 reflects current unprofitability, requiring investors to focus on future earnings potential.
- Gross margin of 16.5% suggests challenges in cost management and pricing strategy.
- Negative beta of -0.72 indicates an inverse correlation with the market, potentially offering diversification benefits but also reflecting business-specific risks.
- Presence in multiple Asian markets including Malaysia, Singapore, and China, provides geographic diversification and access to growing consumer markets.
Competitors & Peers
Strengths
- Diverse product portfolio in health and beauty.
- Presence in multiple Asian markets.
- Manufacturing capabilities for medical devices and consumables.
- Offers private label manufacturing services.
Weaknesses
- Negative profitability metrics (P/E, profit margin).
- Small market capitalization.
- OTC listing indicates higher risk.
- Limited brand recognition compared to larger competitors.
Catalysts
- Upcoming: Expansion of product line with innovative biotech-nutraceutical solutions to address specific health needs.
- Ongoing: Deepening market penetration in existing Asian markets through strengthened distribution and marketing efforts.
- Upcoming: Leveraging e-commerce platforms to reach a wider customer base and increase brand awareness.
- Ongoing: Offering private label manufacturing services to other companies in the health and beauty industry to generate additional revenue.
- Ongoing: Investing in research and development to create proprietary formulations and differentiate from competitors.
Risks
- Potential: Intense competition from established players in the health and beauty industry.
- Potential: Fluctuations in currency exchange rates can impact profitability.
- Potential: Changes in regulatory requirements in different Asian markets.
- Potential: Economic slowdown in key markets can reduce consumer spending.
- Ongoing: Negative profitability metrics (P/E, profit margin) indicate financial challenges.
Growth Opportunities
- Expanding product line with innovative biotech-nutraceutical solutions: DSwiss can capitalize on the growing consumer interest in health and wellness by introducing new products that address specific health needs. The global nutraceuticals market is projected to reach $441.7 billion by 2026, offering a significant opportunity for DSwiss to increase its market share. Timeline: Ongoing.
- Deepening market penetration in existing Asian markets: DSwiss can focus on strengthening its distribution channels and marketing efforts in Malaysia, Singapore, Indonesia, Taiwan, Macau, Hong Kong, and China. The rising disposable incomes and increasing health awareness in these markets provide a favorable environment for DSwiss to grow its sales. Timeline: Ongoing.
- Leveraging e-commerce platforms to reach a wider customer base: DSwiss can expand its online presence by partnering with e-commerce platforms and developing its own online store. The growth of e-commerce in Asia provides a cost-effective way for DSwiss to reach new customers and increase its brand awareness. The e-commerce market in Southeast Asia is expected to reach $172 billion by 2025. Timeline: Upcoming.
- Offering private label manufacturing services to other companies: DSwiss can leverage its manufacturing capabilities to provide private label services to other companies in the health and beauty industry. This can generate additional revenue streams and diversify the company's business model. The private label market is expected to grow at a CAGR of 5.6% from 2021 to 2026. Timeline: Ongoing.
- Investing in research and development to create proprietary formulations: DSwiss can differentiate itself from competitors by developing unique and effective formulations for its products. This requires investing in research and development and building a team of experienced scientists and researchers. Proprietary formulations can command higher prices and create a competitive advantage. Timeline: Ongoing.
Opportunities
- Expanding product line with innovative solutions.
- Deepening market penetration in existing markets.
- Leveraging e-commerce platforms for wider reach.
- Increasing demand for health and wellness products in Asia.
Threats
- Intense competition from established players.
- Fluctuations in currency exchange rates.
- Changes in regulatory requirements.
- Economic slowdown in key markets.
Competitive Advantages
- Proprietary formulations in nutraceutical and skincare products.
- Established distribution network in Asian markets.
- Diverse product portfolio catering to various consumer needs.
- Manufacturing capabilities for medical devices and consumables.
About DQWS
DSwiss, Inc., incorporated in 2015 and headquartered in Kuala Lumpur, Malaysia, operates as a biotech-nutraceutical company focused on the development and distribution of health and beauty products. The company's product portfolio includes DSwiss coffee, designed to promote digestive health; DSwiss kiwi, which supports the immune system and enhances skin complexion; DSwiss Triple SC, targeting stem cell benefits; and a variety of skincare products like the DSwiss silk mask, coffee slimming scrub, peppermint slimming gel, new age essence, and enlighten essence cream. Beyond nutraceuticals and skincare, DSwiss also offers medical devices and consumables, including DSwiss BioSpec eyewear, Genmune-Pro for immune system support, SkinEra for various skin conditions, SensiBath gel, SuiSu hand and air sanitizers, and MasterLiv, MasterHeart, and WellG supplements targeting liver, heart, and metabolic health, respectively. The company provides diagnostic equipment such as the DSwiss quantum magnetic analyzer and AI skin analyzer machine. Additionally, DSwiss offers medical consumables like surgical gowns, masks, and protective eyewear, along with DNA microarray genotyping services. DSwiss distributes its products across Malaysia, Singapore, Indonesia, Taiwan, Macau, Hong Kong, and China, catering to a wide range of consumer health and beauty needs. The company also offers turnkey private label manufacturing services, expanding its reach within the industry.
What They Do
- Develops and distributes health and beauty products.
- Offers nutraceutical products like DSwiss coffee and DSwiss kiwi.
- Provides skincare solutions including masks, scrubs, and essences.
- Manufactures medical devices such as BioSpec eyewear and quantum magnetic analyzers.
- Supplies medical consumables like surgical gowns and masks.
- Offers DNA microarray genotyping services.
- Provides private label manufacturing services.
Business Model
- Direct sales of health and beauty products through various distribution channels.
- Revenue from medical device and consumable sales.
- Income from DNA microarray genotyping services.
- Fees from private label manufacturing services.
Industry Context
DSwiss, Inc. operates within the consumer defensive sector, specifically in the household and personal products industry. This sector is generally characterized by stable demand, as consumers continue to purchase essential goods regardless of economic conditions. The market is competitive, with established players like BABB (BAB, Baby Banz North America), CAWW (Cawwaii Global), CLGOF (Clearly Canadian Beverage Corporation), EWLU (Euro Waste Logistics), and GGII (Green Globe International, Inc.) competing for market share. DSwiss differentiates itself through its focus on biotech-nutraceutical products and its presence in Asian markets. The industry is influenced by trends such as increasing consumer awareness of health and wellness, growing demand for natural and organic products, and the rise of e-commerce.
Key Customers
- Individual consumers seeking health and beauty products.
- Hospitals and clinics purchasing medical devices and consumables.
- Other companies utilizing private label manufacturing services.
Financials
Chart & Info
DSwiss, Inc. (DQWS) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Friday
· Jan 17, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DQWS.
Price Targets
Wall Street price target analysis for DQWS.
MoonshotScore
What does this score mean?
The MoonshotScore rates DQWS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ming Chia Leong
Unknown
Ming Chia Leong leads DSwiss, Inc. with a team of 13 employees. Information regarding Ming Chia Leong's specific background, career history, educational qualifications, and previous roles is not available in the provided data. Therefore, a comprehensive biographical profile cannot be constructed at this time.
Track Record: Due to the limited information available, it is not possible to provide a detailed account of Ming Chia Leong's track record, key achievements, strategic decisions, or company milestones under their leadership. Further data is needed to assess their performance and contributions to DSwiss, Inc.
DQWS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that DSwiss, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures, increasing the risk for investors. This tier is also known as the 'Pink Sheets' market, characterized by speculative stocks and a higher potential for fraud or manipulation. Investing in OTC Other stocks requires significant due diligence and a high-risk tolerance due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spread can lead to price volatility.
- Higher potential for fraud or manipulation due to lack of regulatory oversight.
- OTC Other listing indicates the company may not meet minimum financial standards.
- Difficulty in obtaining reliable information for due diligence.
- Verify the company's registration and legal standing.
- Obtain and review audited financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's debt and cash flow situation.
- Understand the risks associated with the OTC market.
- Consult with a financial advisor before investing.
- Company has been in operation since 2015.
- Offers a diverse range of products and services.
- Presence in multiple Asian markets.
- Provides private label manufacturing services.
What Investors Ask About DSwiss, Inc. (DQWS)
What does DSwiss, Inc. do?
DSwiss, Inc. is a biotech-nutraceutical company that develops, manufactures, and distributes a range of health and beauty products across several Asian markets, including Malaysia, Singapore, and China. Their product line includes nutraceuticals like DSwiss coffee and kiwi, skincare products, medical devices such as BioSpec eyewear, and medical consumables like surgical masks. The company also provides private label manufacturing services, catering to other businesses in the health and beauty sector. DSwiss aims to address consumer needs in digestive health, immunity, and overall well-being through its diverse offerings.
What do analysts say about DQWS stock?
AI analysis is currently pending for DQWS. Due to its OTC listing and small market capitalization, there is limited analyst coverage available. Key valuation metrics such as the negative P/E ratio (-152.18) and low gross margin (16.5%) suggest that the company is currently unprofitable. Growth considerations include expanding its product line, penetrating deeper into existing markets, and leveraging e-commerce platforms. Investors should conduct thorough due diligence and consider the risks associated with investing in a small-cap, OTC-listed company with limited financial information.
What are the main risks for DQWS?
The main risks for DSwiss, Inc. include intense competition from established players in the health and beauty industry, fluctuations in currency exchange rates, and changes in regulatory requirements in different Asian markets. Additionally, the company faces risks associated with its OTC listing, such as limited financial disclosure, low trading volume, and potential for price volatility. The negative profitability metrics (P/E, profit margin) also indicate financial challenges. Investors should carefully consider these risks before investing in DQWS.
What are the key factors to evaluate for DQWS?
DSwiss, Inc. (DQWS) currently holds an AI score of 54/100, indicating moderate score. Key strength: Diverse product portfolio in health and beauty.. Primary risk to monitor: Potential: Intense competition from established players in the health and beauty industry.. This is not financial advice.
How frequently does DQWS data refresh on this page?
DQWS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven DQWS's recent stock price performance?
Recent price movement in DSwiss, Inc. (DQWS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse product portfolio in health and beauty.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider DQWS overvalued or undervalued right now?
Determining whether DSwiss, Inc. (DQWS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying DQWS?
Before investing in DSwiss, Inc. (DQWS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for CEO profile and track record.
- Disclosure status on OTC market is unknown.